June was a busy month for Digital Orthopaedics. During a webinar co-organized with Synopsys, the company’s engineers described how they generate patient-specific digital twins; a mechanical replica of the patient’s foot, using image & motion analysis. This event was followed by Simbio-M, another virtual conference focused on new technologies in the field of biomechanics and[…]
Unique 3M3 tissue regeneration technology platform generates multiple product candidates: autologous, off-the-shelf and miRNA/exosome Novadip Biosciences, a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple product candidates, announces that it will unveil details of its 3M3 miRNA delivery platform in a recorded presentation at the BIO Digital conference, which is took place[…]
Great news for Novadip published in L’Echo and Trends Tendances. Novadip Biosciences – biotech active in cell therapy – has recorded very encouraging results for its product candidate intended to repair large non-healing fractures of the lower limbs in adults. The UCLouvain spin-off has developed a revolutionary process for reconstructing bones from stem cells drawn from the patient’s fat.[…]
Eric Halioua, President & CEO of PDC*line Pharma, was invited on BMF Business to speak about the new class of immunotherapies active against cancer which his team is developing. Watch the replay here: Contact us to get more information: Source: https://bfmbusiness.bfmtv.com/mediaplayer/video/eric-halioua-pdcline-pharma-pdcline-pharma-developpe-une-nouvelle-classe-d-immunotherapies-actives-contre-les-cancers-0205-1244108.html
ReiThera, LEUKOCARE and Univercells announce pan-European consortium for the fast-track development of a single-dose adenovirus-based COVID-19 vaccine. Italian ReiThera Srl. (Rome), German LEUKOCARE AG (Munich), and Belgian Univercells S.A. (Brussels), today announced a strategic collaboration for the development and large-scale manufacturing of a novel adenoviral vector-based vaccine against COVID-19. The vaccine candidate is expected to enter[…]
Savics is collaborating since more than 2 weeks with KU Leuven and DNAlytics to collect, gather and analyze COVID-19 test results. DataToCare COVID-19 is/will be used by all 7 University Laboratories across Belgium that support and unload the Belgian COVID-19 Reference Laboratory from UZ Leuven. DataToCare COVID-19 is a software installed in laboratories that capture COVID-19 test results and[…]
With the novel coronavirus continuing its global spread, drugmakers are pouring massive resources into developing targeted therapies and vaccines. Now, a new CDMO from Belgium’s Univercells is hoping its expertise can help drugmakers scale up their manufacturing for a successful shot. Univercells has launched Exothera, a viral vector CDMO targeting cell and gene therapy and vaccine developers, in a refurbished 15,000-square-meter[…]
Liège, Belgium and Grenoble, France, March 3, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today that the first patient was dosed with its innovative medicinal product candidate PDC*lung01 in a phase I/II trial in non-small cell lung cancer (NSCLC). This patient is under[…]
BRUSSELS, BELGIUM – FEBRUARY 18,2020 — Univercells, an innovative bioprocessing provider focused on increasing the availability of affordable biologics to address global health challenges, has announced up to EUR 50M financing from Gamma Biosciences, a new investment platform supported by leading global investment firm KKR, that is focused on next-generation bioprocessing technologies for the production of advanced[…]
GOSSELIES, BELGIUM – FEBRUARY 14TH, 2020 — OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, today announced that it has completed a €19 million ($20 million) Series B equity financing. The new funding will support rapid international growth, accelerate software development and hiring initiatives. The round was led by Vesalius Biocapital[…]
GOSSELIES, BELGIUM – February 3, 2020 — MaSTherCell S.A., a subsidiary of MaSTherCell Global, Inc., a subsidiary of Orgenesis Inc. (NASDQ: ORGS) a technology-focused cell and gene therapy contract development and manufacturing partner to leading cell therapy innovators, today announced an agreement to acquire MaSTherCell Global that has been reached between the owners of MaSTherCell Global and Catalent Pharma[…]
Check the latest issue of Biotech Finances to read an interview of PDC*line Pharma’s President & CEO Eric Halioua describing the recent fund raising completed and the perspectives of the company. Read the full article: https://www.biotech-finances.com/126504-2/ Contact us to get more information:
Liège, Belgium and Grenoble, France, January 22, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today the completion of its Series B round of financing. The company has raised a total of €20 million ($22.2M). Two and a half years after its last round of[…]
A new article about our customer PDC*line Pharma published in the newspaper L’Echo: with an interview of President & CEO Eric Halioua underlining the achievements made by the company over the last 4 years. Source: https://www.lecho.be/entreprises/pharma-biotechnologie/PDC-line-Pharma-nouvel-espoir-wallon-contre-le-cancer/10191614
Our customer Imcyse is announcing to the world their excellent first-in-human clinical results in Type 1 Diabetes. Imcyse reports successful first-in-human Phase 1b study in type 1 diabetes with IMCY-0098
Proud to have helped Imcyse to fundraise 35M€ to carry out clinical trials of treatments for type 1 diabetes, multiple sclerosis and other autoimmune diseases. Please read the article in L’Echo: https://www.lecho.be/entreprises/pharma-biotechnologie/imcyse-se-profile-comme-la-future-pepite-wallonne-de-la-biotech/10137301.html Imcyse secures total of €35M in Series B financing round and additional grants
B.R.A.I.N. hub (Belgian Research And Innovation in Neurosciences), the second European Human Brain Project’s National Hub for Innovation (HBP-NHI-be), was successfully launched in Belgium thanks to the initiative of Abaxys Therapeutics and our startupstudio.be. Press release: https://gallery.mailchimp.com/86270bb6b0c29cba9301c4907/files/d77b9722-7fd0-4679-9ef4-18cd08f24a6f/BRAINhub_kick_off_press_release_HBP_NHI_be_Mar_2019.pdf?mc_cid=27e3a48b74&mc_eid=6d7be67224
New success story for our customer PDC*line Pharma which enters into a licensing agreement with leading Korean pharmaceutical company LG Chem to develop PDC*lung cancer vaccine in Asia. PDC*line Pharma enters into licensing agreement with LG Chem to develop PDC*lung cancer vaccine in Asia
Our customer Univercells has been awarded a $12 Million grant by the Bill & Melinda Gates Foundation to develop a breakthrough vaccine manufacturing platform. Its aim is to drastically reduce the cost of vaccines whilst increasing their availability and affordability in developing countries. « Humanity’s greatest advances are not in its discoveries, but in how those discoveries[…]
The Deloitte Technology Fast 50 competition is an annual selection of the 50 fastest-growing technology companies within Belgium. The initiative is designed to encourage and promote entrepreneurial, fast-growing technology companies. On Wednesday 19th of November 2015, OncoDNA was named “Most Disruptive Innovator” in the Rising Star category. This award recognises companies that have developed a[…]